Indian drugmakers fret over FDA crackdown; Lanxess expands Saltigo site;

> Specialty chemicals company Lanxess is investing about €60 million ($65 million) to expand a Saltigo site in Leverkusen, Germany. Report

> Indian drugmakers discussed FDA concerns at a meeting recently, with experts acknowledging that some companies need to improve operations to avoid getting Form 483s from the agency. Report

> CDMO Lonza argues the industry is lagging in its use of electronic documentation for quality control. Report

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.